�Agendia, a world leader in molecular cancer diagnostics, announced the launch of TargetPrint(R), a new diagnostic test that
allows physicians to quantitatively determine the gene expression levels of
the oestrogen receptor (ER), progesterone sensory receptor (PR) and Human Epidermal
growth broker Receptor 2 (HER2) in breast cancer tumor biopsies. The
accurate measurement of these receptors is of paramount importance in
planning treatment of breast cancer patients after surgery and assists
physicians and patients in fashioning informed treatment decisions. TargetPrint
runs on Agendia's novel High Density Chip, which received market place clearance
last month (August 2008) from the U.S. Food and Drug Administration (FDA).
"Currently available targeted therapies, such as hormone treatments,
john have a huge shock on the survival and quality of life of a important
number of breast cancer patients," aforesaid Bernhard Sixt, Ph.D., prexy and
top dog executive military officer of Agendia. "TargetPrint will play a key persona in
shaping which patients are to the highest degree likely to benefit from these treatments."
"The test's results break a accurate molecular readout of presage
parameters for breast cancer and provide physicians and patients with
reliable guidance on the most suitable treatment for each single
patient," aforementioned Richard A. Bender, MD, FACP, top dog medical policeman of
Agendia. "In the near future, it is our project to tote up information on a wider
range of drug targets to TargetPrint and clinically validate these with key
customers."
Agendia will acquaint clinical data on TargetPrint at The 2008 Breast
Cancer Symposium which is co-sponsored by the American Society of Clinical
Oncology (ASCO) and will be held in Washington, DC from September 5-7,
2008. TargetPrint is processed at Agendia's Clinical Laboratory Improvement
Amendments (CLIA) certified and the College of American Pathology (CAP)
accredited laboratory.
About Agendia
Agendia is a world leader in molecular cancer diagnostics. The company
markets quatern products based on its breakthrough platform for tumour gene
expression profiling and has several new symptomatic tests below
development. Agendia was the first fellowship to welcome FDA clearance for a
breast cancer test, MammaPrint(R), that predicts the risk of exposure of breast cancer
return. In addition, the company collaborates with pharma companies to
make grow highly effective personalized drugs in the area of oncology.
Agendia is based in Huntington Beach, California, and in Amsterdam, The
Netherlands. For more information on Agendia, please visit http://www.agendia.com.
Agendia
http://www.agendia.com
More info
Sunday, 7 September 2008
Subscribe to:
Comments (Atom)